X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used for the first-in-human phase 1 trial of DP-023, an Allogeneic Natural Killer (NK) Cell Therapy in patients with multiple myeloma and lymphoma.
Lead Product(s): IDP-023,Antibody
Therapeutic Area: Oncology Product Name: IDP-023
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Indapta Therapeutics
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 17, 2023
Details:
Boundless Bio will use the financing to advance BBI-355, a potentially best-in-class checkpoint kinase 1 inhibitor and the first ecDNA-directed therapy, through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers.
Lead Product(s): ecDNA-directed Therapy
Therapeutic Area: Oncology Product Name: BBI-355
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Boundless Bio
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 16, 2023
Details:
The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: NextPoint
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 10, 2023
Details:
Proceeds from the financing will be used to fund the diversification of ReCode’s pipeline into central nervous system, liver, and oncology indications, while continuing to advance lead mRNA programs for primary ciliary dyskinesia and cystic fibrosis into the clinic.
Lead Product(s): SORT LNP-based DNAI1 mRNA Therapeutic
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: ReCode Therapeutics
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 29, 2022
Details:
Senti’s existing investors continue to support the mission of engineering gene circuits with programmable logic in cell and gene therapies, and progress in advancing multiple oncology programs including SENTI-202, towards the clinic.
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Senti Biosciences
Deal Size: $5.2 million Upfront Cash: Undisclosed
Deal Type: Financing May 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
